We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

ADV-TK Improves Outcome of Recurrent High-Grade Glioma (HGG-01)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00870181
First Posted: March 27, 2009
Last Update Posted: June 25, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Beijing Tiantan Hospital
Beijing Chao Yang Hospital
Beijing Friendship Hospital
Information provided by (Responsible Party):
Ding Ma, Huazhong University of Science and Technology
  Purpose
Malignant gliomas are the most common primary brain tumor in adults, but the prognosis for patients with these tumors remains poor despite advances in diagnosis and standard therapies such as surgery, radiation therapy, and chemotherapy. The advantages of ADV-TK gene therapy highlight its efficacy and safety for glioma patients. This clinical trial was conducted to assess the anti-tumor efficacy and safety of intraarterial cerebral infusion of replication-deficient adenovirus mutant ADV-TK, in combination with systemic intravenous GCV administration in patients with recurrent high-grade glioma.

Condition Intervention Phase
Malignant Glioma of Brain Glioblastoma Biological: ADV-TK/GCV Procedure: Surgery Drug: systemic chemotherapy Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Adenovirus-Mediated Delivery of Herpes Simplex Virus Thymidine Kinase Administration Improves Outcome of Recurrent High-Grade Glioma

Resource links provided by NLM:


Further study details as provided by Ding Ma, Huazhong University of Science and Technology:

Primary Outcome Measures:
  • The primary end point was 6-month progression-free survival rate (PFS-6) [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • progression-free survival (PFS) [ Time Frame: 3 years ]
  • overall survival (OS) [ Time Frame: 3 years ]
  • safety [ Time Frame: 1. at the time during treatments; 2. at 6-month; 3. at the end of 1-year following-up; 4. at the end of 2-year following up; 5. at the time the patient censored. ]
  • clinical benefit [ Time Frame: at the end of 2nd ADK-TK/GCV therapy ]
    the rate of complete response, plus partial response, plus stable disease


Enrollment: 47
Study Start Date: January 2008
Study Completion Date: December 2012
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ADV-TK/GCV
ADV-TK was administered via intraarterial cerebral infusion. Systemic GCV therapy was delivered at a dose of 5mg/kg intravenous, every 12 h at 36 hours after ADV-TK therapy.
Biological: ADV-TK/GCV
gene therapy
Active Comparator: Control group
Patients received surgery or systemic chemotherapy or palliative care.
Procedure: Surgery Drug: systemic chemotherapy

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed WHO grades 3 to 4 malignant glioma
  • Diagnosed recurrence or progression by clinical or radiological evidence
  • Fit for intraarterial infusion and intravenous chemotherapy
  • Adequate hepatic, renal, and hematologic function.
  • Legal age ≥18 years
  • Life expectancy ≥12 weeks
  • Eastern Cooperative Oncology Group performance (ECOG) ≥2
  • Chemotherapy completion ≥4 weeks prior and recovery from drug induced toxicities.

Exclusion Criteria:

  • Active pregnancy
  • Prior gene therapy
  • Second primary tumor
  • Gravidity, lactation, hypersensitivity to antiviral drugs, immunologic deficit, active uncontrolled infections
  • Requiring treatment with warfarin or any other anticoagulants
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00870181


Locations
China, Beijing
Beijing YouAn Hospital
Beijing, Beijing, China, 100069
Sponsors and Collaborators
Huazhong University of Science and Technology
Beijing Tiantan Hospital
Beijing Chao Yang Hospital
Beijing Friendship Hospital
Investigators
Study Director: Ma Ding, M.D. Tongji Hospital of HUST
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Ding Ma, Director of Department of Gynecology and Obstetrics, Huazhong University of Science and Technology
ClinicalTrials.gov Identifier: NCT00870181     History of Changes
Other Study ID Numbers: 2009HGG-01
First Submitted: March 26, 2009
First Posted: March 27, 2009
Last Update Posted: June 25, 2013
Last Verified: June 2013

Additional relevant MeSH terms:
Glioblastoma
Glioma
Astrocytoma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue